Epoch Investment Partners Inc. Trims Stock Position in Lantheus Holdings, Inc. $LNTH

Epoch Investment Partners Inc. lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.6% during the 4th quarter, Holdings Channel reports. The firm owned 407,529 shares of the medical equipment provider’s stock after selling 48,326 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Lantheus were worth $27,121,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Quantbot Technologies LP purchased a new stake in shares of Lantheus in the third quarter valued at about $1,847,000. Assetmark Inc. lifted its holdings in shares of Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after purchasing an additional 19,844 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after purchasing an additional 115,338 shares in the last quarter. Heron Bay Capital Management purchased a new stake in shares of Lantheus in the third quarter valued at about $861,000. Finally, Isthmus Partners LLC purchased a new stake in shares of Lantheus in the third quarter valued at about $1,238,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $104.52 on Monday. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The company has a market cap of $6.81 billion, a P/E ratio of 25.19 and a beta of -0.03. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $104.57. The firm’s 50 day moving average is $90.68 and its two-hundred day moving average is $76.78.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The company had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. Lantheus’s revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus Holdings, Inc. will post 4.39 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LNTH. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Citizens Jmp upped their price objective on shares of Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. William Blair reissued an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Finally, Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.